Clinical trial
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19…
NCT04634409 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT04634409 |
|---|---|
| Title | A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness |
| Official title | A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4) |
| Acronym | BLAZE-4 |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | AbCellera Biologics Inc. Industry Shanghai Junshi Bioscience Co., Ltd. GlaxoSmithKline Vir Biotechnology, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | COVID-19 |
| Intervention type | Drug |
| Interventions | Bamlanivimab, Etesevimab, Placebo, VIR-7831, Bebtelovimab |
| Enrollment | 1,755 |
| Start date | Oct 29, 2020 |
| Primary completion | Jul 27, 2021 |
| Completion | Oct 18, 2021 |
| First posted | Nov 18, 2020 |
| Last update posted | Jul 1, 2022 |
| Countries | Argentina, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: